A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT01683409
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT01683409
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Japan, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01683409. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2017-07-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Baricitinib
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
- Collaborator
- Incyte Corporation
Record details
- Record id
cardio:ct-nct01683409- Content hash
fe2b2db1c7ac74440bd9be80738040f0b0c89a474231230f47a6a9b2fec866b9